Geneplus locks onto targeted medicine for IPO pitch
After a post-Covid earnings dip, the company is seeking a stable future as a provider of data and diagnostics for precision medicine and disease prevention Key Takeaways: The company’s…
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
Sainte Nutritional ladles up sinking business in renewed IPO application
The special-purpose formula maker’s net profit rose in the first half of this year, but the gains were due to factors unrelated to its core business Key Takeaways: Sainte Nutritional…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
Ming Yu seeks a share of the drug sector limelight
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:…
Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
CSPC feels the pain from sweeping cuts in drug prices
The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…
Recent Articles
RELATED ARTICLES
-
Dongshan Precision offers investors an acquisitive, but debt heavy, tech component play
002384.SHE - IPO hopeful Distinct Healthcare targets the well-to-do market
- WUS Printed Circuit charges up Hong Kong’s growing tech pool
- Declining revenues, widening losses remove polish from Hiducation IPO
- Fresh from its first profit, Medcaptain steps into IPO spotlight
-
Years of losses, thin profit margins leave 160 Health feeling down
2656.HK
-
Neglected Burning Rock charms investors with high margins, narrowing losses
BNR.US
